Nasdaq:IMPL

<!-- Name:DistributionId Value:8806815 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:4570 -->…

<!-- Name:DistributionId Value:8754799 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:4570 -->…

TRUDHESA Is the First and Only Therapeutic to Use POD technology to Deliver Dihydroergotamine Mesylate (DHE) to the Vascular-Rich Upper Nasal Space TRUDHESA Is Well Tolerated and Delivers Rapid, Sustained and Consistent Symptom Relief for…

SEATTLE, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Impel NeuroPharma, Inc. (NASDAQ: IMPL), a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients living with central…

SEATTLE, July 07, 2021 (GLOBE NEWSWIRE) -- Impel NeuroPharma, Inc. (Impel), a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients living with central nervous…